Pfizer Elrexfio — Revenues: increased by 8.1% to $80.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 33.3%, from $60.00M to $80.00M.
pfe_segment_elrexfio_revenues| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $2.50M | $2.50M | $2.50M | $2.50M | $13.00M | $22.00M | $40.00M | $57.00M | $60.00M | $85.00M | $85.00M | $74.00M | $80.00M |
| QoQ Change | — | — | — | — | — | +0.0% | +0.0% | +0.0% | +420.0% | +69.2% | +81.8% | +42.5% | +5.3% | +41.7% | +0.0% | -12.9% | +8.1% |
| YoY Change | — | — | — | — | — | — | — | — | +420.0% | +780.0% | >999% | >999% | +361.5% | +286.4% | +112.5% | +29.8% | +33.3% |